Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding episodes and peri‑operative prophylaxis in patients with specific clotting factor deficiencies.

• Treatment of acute bleeding in hemophilia A patients.
• Prevention of bleeding during surgical or dental procedures in hemophilia A.
• Management of bleeding episodes in von Willebrand disease types 1 and 3.
• Long‑term prophylaxis to reduce frequency of spontaneous bleeds in severe hemophilia A.
• Replacement therapy in patients with combined factor VIII and von Willebrand factor deficiency.
• Support of hemostasis in patients undergoing major trauma when factor levels are low.

Adverse reactions to Haemate P have been reported, ranging from mild infusion‑related events to rare serious complications.

Common

• Headache or mild fever.
• Transient nausea or vomiting.
• Localized infusion site reactions such as erythema or swelling.
• Mild arthralgia or joint discomfort.
• Fatigue or malaise.

Serious

• Development of inhibitors (antibodies) against factor VIII.
• Anaphylactic or severe allergic reactions.
• Transmission of infectious agents (theoretical risk despite viral inactivation).
• Thrombotic events (rare).

Clinicians should consider several precautionary measures before prescribing Haemate P to ensure patient safety and optimal therapeutic outcomes.

• Assess baseline factor VIII activity and von Willebrand factor levels.
• Screen for history of inhibitors or allergic reactions to plasma‑derived products.
• Evaluate for active infections or recent vaccinations.
• Use caution in patients with cardiovascular disease due to potential thrombotic risk.
• Monitor for signs of inhibitor development during treatment.
• Adjust dosing in patients with renal or hepatic impairment as needed.

Haemate P may interact with other medications that affect hemostasis or immune response, requiring careful management.

Avoid

• Concurrent use of other factor concentrates without medical supervision.
• Administration with high‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.
• Use with investigational gene‑therapy agents targeting factor VIII without specialist oversight.
• Combination with desmopressin (DDAVP) in von Willebrand disease without dose adjustment.

Use with caution

• Concomitant anticoagulants such as warfarin or direct oral anticoagulants; monitor coagulation parameters closely.
• Immunosuppressive therapies that may alter inhibitor formation; observe for reduced efficacy.
• Vaccinations administered shortly before or after infusion; consider timing to minimize immune reactions.
• Use with heparin; monitor activated partial thromboplastin time (aPTT).